Sanara MedTech (NASDAQ:SMTI) announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, along with initial guidance for 2026.
Fourth-quarter 2025 revenue is expected to be in the range of $27.2 million to $27.7 million, representing approximately 3% to 5% growth year-over-year, or 11% to 13% when excluding $1.8 million in non-recurring BIASURGE sales from the prior-year period.
Full-year 2025 revenue is anticipated at $102.7 million to $103.2 million, reflecting roughly 19% growth, or 21% to 22% excluding the BIASURGE item.
As of December 31, 2025, the company had approximately $16.6 million in cash and long-term debt of approximately $46 million.
Operational highlights during the period under review included securing a Vizient Innovative Technology contract for BIASURGE, enhancing access to this advanced surgical solution across Vizient member networks.
The company also continued collaboration with Biomimetic Innovations on OsStic, a next-generation bone graft substitute, with U.S. commercial introduction targeted for the first quarter of 2027 pending FDA clearance.
For fiscal 2026, Sanara MedTech issued revenue guidance of $116 million to $121 million, implying 13% to 17% growth from the midpoint of its preliminary 2025 results.
The figures remain preliminary and unaudited, subject to final year-end close and audit adjustments.